The prognostic significance of human papillomavirus (hpv) infections and cancer screening

CME Journal of Gynecologic Oncology

Volumn 6, Issue 3, 2001, Pages 325-346

  Syrjanen K J ^a   Erzen M ^a  

^a NONE   (Finland)

Author keywords

Cervical cancer; HPV infections; Prognosis; Screening

Indexed keywords

CANCER SCREENING; FEMALE; FINLAND; HUMAN; ICELAND; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SWEDEN; TECHNOLOGY; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS DIAGNOSIS; VIRUS INFECTION; VIRUS TRANSMISSION; WART VIRUS;

EID: 0035678404     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (181)

1. Cervical intraepithelial neoplasia and cervical cancer
2. Racial differences in cervical cancer mortality in Chicago
3. Strategies for global control of cervical cancer
4. Report on a workshop of the UICC Project on evaluation of screening for cancer
5. Screening for cervical cancer: Experience from the Nordic Countries
6. The Pap test: George N. Papanicolaou (1883-1962). A screening test for the prevention of cancer of uterine cervix
7. Report on consensus conference on cervical cancer screening and management
8. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: Recent increase in cervical cancer incidence
9. Early detection of CIN, HPV and prevention of cervical cancer
10. The Icelandic and Nordic cervical screening programs: Trends in incidence and mortality rates through 1995
11. Barriers to Pacific women's use of cervical screening services
12. Estimates of the worldwide incidence of 25 major cancers in 1990
13. New developments in cervical cancer screening and prevention
14. Viral etiology of cervical cancer: A critique of the evidence
15. The sexually transmitted disease model for cervical cancer: Incoherent epidemiologic findings and the role of misclassification of human papillomavirus infection
16. Risk factors for invasive cervix cancer in young women
17. Genital Human papillomavirus (HPV) infections and their associations with squamous cell cancer: Reapprisal of the morphologic, epidemiologic and DNA data
18. Biological behaviour of cervical intraepithelial neoplasia
19. Statistical issues in human papillomavirus testing and screening
20. Global burden of cancer
21. Workshop on screening for cancer of the uterine cervix in Central America
22. Screening for the 21st century: Learning from the past
23. Natural history of cervical intracpithelial neoplasia - A critical review
24. Dysplasia of the uterine cervix
25. Cervical intraepithelial neoplasia
26. Human papillomavirus investigation of patients with cervical intraepithelial neoplasia 3, some of whom progressed to invasive cancer
27. Screening for squamous cell cancer: The duration of low risk after negative result of cervical cytology and its implications for screening policies
28. Papanicolaou test and enzyme-linked in-situ hybridization. A combined diagnostic system for papilloma virus infections with high prognostic value
29. DNA content measurement and in situ hybridization in condylomatous cervical lesions
30. Correlations between the HPV type, DNA index and evolution of cervical intraepithelial neoplasia (CIN)
31. Human papillomavims infection and the size and grade of cervical intraepithelial neoplastic lesions associated with failure of therapy
32. Typing of human papillomaviruses in intra-epithelial malpighian lesions of the cervix uteri: Correlation with cytohistologic grade and progression of the lesions
33. Expression of human papillomavirus type 16 E6-E7 open reading frame varies quantitatively in biopsy tissue from different grades of cervical intraepithelial neoplasia
34. High-risk human papillomavirus infection and E6 protein expression in lesions of the uterine cervix
35. Labelling pattern obtained by non-isotopic in situ hybridization as a prognostic factor in HPV-associated lesions
36. HPV, histologic grade and age. Risk factors for the progression of cervical intraepithelial neoplasia
37. Epidemiological aspects of human papillomavirus infection and cervical cancer in Brazil
38. Prognostic factors in cervical human papillomavirus (HPV) infections
39. Can HPV typing predict the behaviour of cervical epithelial neoplasia?
40. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia
41. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri
42. The natural history of CIN 1 lesions
43. Management of low-grade CIN: Follow-up or treatment
44. Screening for cancer: Future potential
45. Screening for genital human papillomavirus: Results from an international validation study on human papillomavirus sampling techniques
46. Screening. The next century
47. Human papillomavirus testing as a screening tool for cervical cancer
48. Possible prognostic significance of human papillomavirus type in cervical cancer
49. Prognostic significance of the presence of human papillomavirus DNA in patients with invasive carcinoma of the cervix
50. Human papillomavirus genotype as a prognostic indicator in carcinoma of the uterine cervix
51. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA
52. Prognostic significance of nuclear DNA content and human papillomavirus (HPV) type in invasivc ccrvical cancer. Polymerase chain reaction (PCR) and flow cytometric analysis
53. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA
54. Prognostic importance of human papillomavirus type 16 DNA in cervical cancer
55. Squamous cell carcinoma of the cervix: HPV 16 and DNA ploidy as predictors of survival
56. Prognostic value of human papillomavirus in the survival of cervical cancer patients: An overview of the evidence
57. Human papillomavirus and its prognostic significanee in invasive carcinoma of the cervix in young patients
58. Human papillomaviruses and other influences on survival from cervical cancer in Panama
59. Human papillomavirus type 16 in tumour tissue of low-stage squamous carcinoma of the uterine cervix in relation to ploidy grade and prognosis
60. Prognostic significance of human papillomavirus detected with polymerasc chain reaction in cervical cancer
61. HPV DNA presence and HPV genotypes as prognostic factors in low-stage squamuus cell cervical cancer
62. The genotypes and prognostic significance of human papillomaviruscs in cervical cancer
63. HPV genotype as a prognostic factor for progression to cervical carcinoma in young women
64. Human papillomavirus DNA in cervical carcinoma - Correlation with clinical data and influence on prognosis
65. The human papillomavirus status of invasive cervical adenocarcinoma: A clinicopathological and outcome analysis
66. Human papillomavirus deoxyribonucleic acid as a prognostic indicator in early-stage cervical cancer: A possible role for type 18
67. Human papillomavirus and disease-free survival in FIGO stage IB cervical cancer
68. Human papillomavirus DNA in invasive cervical carcinomas and its association with patient survival: A nested case-control study
69. Human papillomavirus has no prognostic significance in cervical carcinoma
70. Human papillomavirus type 18: Association with poor prognosis in early stage cervical cancer
71. Type of human papillomavirus is related to clinical features of cervical carcinoma
72. Cervical cancer in young women in Taiwan: Prognosis is independent of papillomavirus or tumour cell type
73. Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer
74. Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis
75. Human papillomavirus genotype as a major determinant of the course of cervical cancer
76. Detection and typing of human papillomavirus in cervical carcinomas in Russian women: A prognostic study
77. Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types
78. Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive ccrvical cancers
79. Prognostic significance of polymerase chain reaction detected human papillomavirus of tumours and lymph nodes in surgically treated stage IB cervical cancer
80. Detection of human papillomaviruses from histologically normal lymph nodes of Japancsc ccrvical cancer patients by nested polymerase chain- reaction assay
81. Human papillomavirus detection in cervical carcinoma tissues and paraaortic lymph nodes by the polymerase chain reaction
82. Correlation of human papillomavirus 16 and 18 with prognostic factors in invasive cervical neoplasias
83. HPV- and node status in cervical cancer long-term results
84. The role of high risk HPV lymph node positivity in the surgical staging of cancer of the uterine cervix
85. Detection of HPV-16 DNA by PCR in histologically cancer free lymph nodes from patients with cervical cancer
86. Presence of human papilloma virus DNA in pelvic lymph nodes can predict unexpected recurrence of cervical cancer in patients with histologically negative lymph nodes
87. Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer
88. Serum antibody responses against human papillomavirus in relation to tumour characteristics, response to treatment, and survival in carcinoma of the uterine cervix
89. Antibodies to human papillomavims type 16 E7 related to elinicopathological data in patients with cervical carcinoma
90. Relation between HPV-16 serology and clinico-pathological data in cervical carcinoma patients: Prognostic value of anti-E6 and/or anti-E7 antibodies
91. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer
92. Detection of human papillomavirus types 16 and 18 mRNA in peripheral blood of advaneed cervical cancer patients and its association with prognosis
93. The epidemiological basis for evaluating screening policies
94. Screening for cervix cancer in developing countries
95. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017
96. Opportunistic screening for cervical cancer
97. Opportunistie cervical screening among 50-70 year olds. A prospeelive study in general practice
98. Potential contribution of screening to cancer mortality reduction
99. To screen or not to screen for cervical cancer
100. Estimates of the worldwide incidence of 18 major cancers in 1985
101. Implementation and evaluation of cervical cancer screening programmes in the European Union
102. Organization and results of cervical cancer screening in Europe over the past 20 years
103. A review of cervical cancer screening intervention research: Implications for public health programs and future research
104. Cervical cancer screening in primary care: Issues and recommendations
105. A randomised controlled trial of strategies to prompt attendance for a Pap smear
106. Characteristics of subgroups of attenders and non-attenders in an organised screening programme for cervical cancer
107. Survival trend after invasive cervical cancer diagnosis in Sweden before and after cytologic screening. 1960-1984
108. Cervical mass screening in Norway - 510,000 smears a year
109. Mass screening against cervical cancer. Nationwide invitations of women start now
110. Mass screening for cervical cancer in Norway: Evaluation of the pilot project
111. Quality assurance in the cytopathology laboratories of the Finnish Cancer Society
112. Organised vs. spontaneous Pap-smear screening for cervical cancer: A case-control study
113. The impact of screening on the incidence of cervical cancer in England and Wales
114. Screening that failed to work
115. Reasons that some screening programmes fail to control cervical cancer
116. The cervical screening muddle
117. Cervical (Pap) smear. New directions
118. The epidemiological basis for evaluating different screening policies
119. IARC working group on cervical cancer screening: Summary chapter
120. Evaluation of the impact of screening for cancer of the cervix
121. Incidence of cervical intraepithelial neoplasia grade III, and cancer of the cervix uteri following a negative Pap-smear in an opportunistic screening
122. Cytological screening and management of abnormalities in prevention of cervical cancer: An overview with stochastic modelling
123. Evaluating cervical cancer screening programmes for developing countries
124. Withdrawing low risk women from cervical screening programmes: Mathematical modelling study
125. Behavior of mild cervical dysplasia during long term follow-up
126. Optimization of cervical cancer screening
127. Quality assurance in cervical cancer screening: The Icelandic experience 1964-1993
128. Cancer incidence in Finland 1995. Cancer Statistics of the National Research and Development Centre for Welfare and Health
129. Preventive examinations for cervix cancer in Denmark. Status in 1995. Plans for 1996
130. Screening for cervix cancer
131. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population
132. Prevalence of genital human papillomavirus (HPV) infections in a mass-screened Finnish female population aged 20-65 years
133. International incidence rates of invasive cervical cancer before cytological screening
134. Mass screening for cervical cancer in Iceland during 1965-1969 and the effect on incidence and mortality
135. Effect of population screening for carcinoma of the uterine cervix in Finland
136. Smear misclassification in a cervical cancer screening programme
137. Evaluation of screening for cervical cancer in Sweden: Trends in incidence and mortality 1958-1980
138. Incidence and mortality of uterine cervix cancer in Norway. When do we get organized nation-wide cytologic screening in Norway?
139. Does screening by PAP smears help prevent cervical cancer? A case-control study
140. The impact of vaginal cytology on cervical cancer risks in Cali, Colombia
141. Pap smear and the risk of cervical neoplasia: Quantitative estimates from a case-control study
142. A case-control study for the evaluation of the cytological detection of cancer of the cervix
143. A case-control study of cervical cancer screening in North-East Scotland
144. Efficacy of screening in preventing invasive cervical cancer: A case-control study in Milan, Italy
145. Cervical cancer screening in Iceland: A case-control study
146. Risk factors for invasive cervical cancer and reduction of risk by Pap smears in Thai women
147. Cervical cancer screening practices among older women: Results from the Maryland Cervical Cancer Case-Control Study
148. A case-control study of cervical cytology before diagnosis of cervical cancer in Denmark
149. A case-control study of the effectiveness of cervical cancer screening in Osaka, Japan
150. Population-based case-control study on cancer screening
151. The effectiveness of cervical screening: A population-based case-control study
152. Papanicolaou smear screening interval and risk of cervical cancer
153. Cervical screening attendance and its effectiveness in a rural population in China
154. Case-control studies of screening
155. Screening for cervical cancer in Latin America. A case-control study
156. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer
157. Risk factors for cervical cancer: Comments on attributable risk calculations and the evaluation of screening in case-control studies
158. An evaluation of a campaign to increase cervical cancer screening in rural Victoria
159. Comparison of the clinical features of uterine cervical cancers detected by mass screening and voluntary visit
160. Population screening for cervical cancer in The Netherlands A report by the Evaluation Committee
161. Screening as a prognostic factor in cervical cancer: Analysis of survival and prognostic factors based on Icelandic population data, 1964-1988
162. Characteristics of uterine cancer detected by mass screening
163. Clinical role of HPV testing
164. Hybrid Capture method for detection of human papillomavirus DNA in clinical specimens: A tool for clinical management of equivocal Pap smears and for population screening
165. Relevance of human papillomavirus screening in management of cervical intraepithelial neoplasia
166. A systematic review of the role of human papillomavirus testing within a cervical screening programme
167. Human papillomavirus testing for primary cervical cancer screening
168. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears
169. Visual inspection as a screenming test for cervical cancer control in developing countries
170. Prevention measures in the third world: Are they practical?
171. Visual inspection with acetic acid in the early detection of cervical cancer and precursors
172. Human papillomavirus (HPV) typing as an adjunct to cervical cancer screening
173. Estimates of the cost impact of introducing Human papillomavirus testing into cervical screening programme
174. Management of abnormal PAP smears (MAPS): Implications of terminology used in cytopathology
175. Use of person-years of CIN 3 exposure as a surrogate outcome measure in cervical cancer screening trials
176. The case against routine HPV testing in cervical screening